McKinsey Vet Franck Le Deu Joins Nisa Leung’s New Fund; Plus C-Suite Shuffle at Bicycle

Why It Matters

Le Deu’s move brings deep strategic consulting expertise to Aulis, enhancing its ability to source and scale cross‑border biotech deals, while the Bicycle leadership shift signals intensified competition for talent in the health‑tech arena.

Key Takeaways

• Franck Le Deu becomes venture partner at Aulis Capital
• Aulis targets East‑West biotech and health‑tech startups
• Fund leverages China’s growing biopharma transformation
• Le Deu previously led McKinsey’s Greater China healthcare practice
• Bicycle announces new C‑suite appointments

Pulse Analysis

The pace of capital flowing into China’s biotechnology sector has accelerated dramatically over the past five years, driven by supportive government policies, a growing pipeline of innovative therapeutics, and an expanding pool of skilled scientists. Investors are increasingly looking for vehicles that can navigate both the regulatory landscape in China and the commercial realities of Western markets. Aulis Capital, founded by Nisa Le U​ng—renowned for building Qiming Venture Partners into one of China’s premier VC firms—positions itself as a bridge, targeting early‑stage biotech and health‑tech companies that can leverage China’s scale while accessing global distribution networks.

Franck Le Deu’s appointment as venture partner adds a rare blend of strategic consulting acumen and hands‑on venture experience to Aulis. At McKinsey, he led the Greater China healthcare practice and co‑directed the firm’s Asia healthcare portfolio, advising multinational pharma executives on market entry, pricing, and R&D strategy. After departing McKinsey, he founded KerZheng Ventures, further sharpening his deal‑sourcing instincts in the region. His deep network of industry leaders, combined with analytical rigor, equips Aulis to evaluate complex scientific platforms, negotiate term sheets, and accelerate portfolio companies toward cross‑border commercialization.

The concurrent C‑suite reshuffle at Bicycle—a fast‑growing health‑tech platform—highlights a broader talent war as firms vie for leaders who can blend technology insight with commercial execution. Such leadership changes often signal strategic pivots, whether toward new therapeutic areas, geographic expansion, or partnership models. For Aulis, Le Deu’s entry and the industry’s heightened focus on executive expertise suggest that capital providers are prioritizing not just funding but also operational guidance to de‑risk investments. As China continues to shape the global biopharma landscape, firms that combine local insight with international reach are likely to capture the most compelling growth opportunities.